1. Scrip

Behind The First Inhaled COVID Vaccine: Chinese-Language CEO Podcast With CanSino’s Xuefeng Yu

Plus: Trials In Emerging Markets, Overseas Collaborations

 
• By Brian Yang

After securing the first approval globally for an inhaled COVID-19 vaccine, Chinese biotech CanSino CEO Xuefeng Yu sat down with Scrip in this Chinese-language interview to share his views on vaccine development and market opportunities in China and elsewhere.

China Biotech CEO Podcast
Chinese-language CEO podcast • Source: Shutterstock

CanSino Biologics Inc.’s co-founder and CEO Xuefeng Yu sits down with Scrip in the first Chinese-language edition of the Biotech CEO Podcast.

Yu has years of experience working at multinational vaccine group Sanofi Pasteur and along with his co-founders transformed a vaccine start-up in Tianjin to a dual Hong Kong- and mainland-listed operation, driven in large part by China’s

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from China

China Biopharma Podcast - 14 May 2025 (Chinese Language)

 
• By Dexter Jie Yan and Xu Hu

Join our China-based editors Dexter Yan and Xu Hu in this Chinese-language podcast looking at some of their recent interviews and other key coverage.

Insilico Fast-Tracks First AI-Designed TNIK Inhibitor For IPF

 
• By Dexter Jie Yan

InSilico will leapfrog Phase IIb to progress its AI-generated candidate for idiopathic pulmonary fibrosis directly into a Phase III trial in China, as it prepares for an IPO in Hong Kong.

Chinese Vaccine Makers Turn To Emerging Markets

 
• By Dexter Jie Yan

Chinese producers of novel vaccines are increasingly pivoting to developing markets overseas in the face of a collapse in their domestic sales.

Chinese Firms Build Obesity Clinical Pipeline But Face Wider Hurdles

 
• By Xu Hu

Despite the ability to initiate clinical trials quickly and having strong manufacturing capacity, Chinese companies are facing multiple challenges in the obesity space.

More from Focus On Asia